Get In Touch
Contact
We welcome conversations with strategic partners, investors,
and healthcare professionals.
The Opportunity
The AIC Opportunity
A large, underserved market. A de-risked asset. A clear path to NDA.
Strategic Highlights
F14 addresses a clear unmet need — current standard of care relies heavily on opioids and systemic NSAIDs with significant side effect burdens
Celecoxib is a well-characterized, FDA-approved COX-2 inhibitor — F14's innovation is the delivery system, not an unproven molecule
A Phase 2 study and a Phase 3 registration trial were completed with favorable safety and consistent efficacy results
A second Phase 3 registration trial will be initiated in 2026 — NDA submission targeted for 2028
Potential reimbursement pathway through the NOPAIN Act for non-opioid pain therapies
Multiple exit pathways: strategic partnership, licensing to a large orthopedic or pharma company, or standalone NDA and commercialization
Development Timeline
Contact Us
We are actively engaging with strategic partners and investors who share our conviction that non-opioid post-surgical therapies are one of the most important unmet needs in orthopedics.
Forward-Looking Statements: This website may contain forward-looking statements regarding AIC's clinical programs, timelines, and business plans. These statements involve risks and uncertainties and are not guarantees of future performance. Actual results may differ materially from those anticipated.